1.	Phase I/II Study of Imexon and Dacarbazine in Patients With Chemotherapy-Naive Unresectable Stage III or IV Melanoma Phase: Phase II, Phase I Type: Treatment Status: Closed Age: unspecified Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: AMP-005, UCLA-0504069, NCT00327600
2.	Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AMP-007, NCT00327249
3.	A Randomized Study of Amplimexon (Imexon) With Gemcitabine in Pancreatic Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AMP-019, NCT00637247
4.	Safety Study of Imexon Treatment of Patients With Metastatic or Disseminated Malignancy Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AMP-011, NCT00327223
5.	Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AMP-010, NCT00327288
6.	Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AMP-004, NCT00327327